Tarsus Pharmaceuticals/TARS

0.86%
-
1D1W1MYTD1YMAX

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04, a novel gel formulation of lotilaner for the potential treatment of rosacea, and TP-05, a novel investigative oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

Ticker

TARS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Bobak Azamian

Employees

244

Headquarters

Irvine, United States

TARS Metrics

BasicAdvanced
US$1.4B
Market cap
-
P/E ratio
-US$4.72
EPS
1.16
Beta
-
Dividend rate
US$1.4B
1.16401
US$42.50
US$12.57
704K
8.012
7.917
10.876
10.876
-52.88%
-66.07%
-58.73%
33.946
5.245
5.323
53.22%
-91.44%

What the Analysts think about TARS

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
48.77% upside
High US$67.00
Low US$34.00
US$38.57
Current price
US$57.38
Average price target

TARS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-129.34% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$28M
112.31%
Net income
-US$36M
-14.8%
Profit margin
-129.34%
-59.87%

TARS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.17%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-US$1.17
-US$1.28
-US$1.31
-US$1.01
-
Expected
-US$1.08
-US$1.37
-US$1.36
-US$1.20
-US$0.93
Surprise
8.48%
-6.26%
-3.86%
-16.17%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Tarsus Pharmaceuticals stock?

Tarsus Pharmaceuticals (TARS) has a market cap of $1.4B as of May 20, 2024.

What is the P/E ratio for Tarsus Pharmaceuticals stock?

The price to earnings (P/E) ratio for Tarsus Pharmaceuticals (TARS) stock is 0 as of May 20, 2024.

Does Tarsus Pharmaceuticals stock pay dividends?

No, Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Tarsus Pharmaceuticals dividend payment date?

Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders.

What is the beta indicator for Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (TARS) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Tarsus Pharmaceuticals stock price target?

The target price for Tarsus Pharmaceuticals (TARS) stock is $57.38, which is 48.15% above the current price of $38.73. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Tarsus Pharmaceuticals stock

Buy or sell Tarsus Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing